AZURITY PHARMACEUTICALS – ARYNTA™: FDA APPROVES ARYNTA™ – AZURITY’S ORAL SOLUTION FOR PEDIATRIC ADHD

The FDA approved ARYNTA™ (lisdexamphetamine dimesylate), an oral solution developed by Azurity Pharmaceuticals for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD). This formulation provides an accessible and flexible treatment option for pediatric patients requiring stimulant therapy in liquid form.

The pharmaceutical brand name ARYNTA™, created by Want Branding, underwent comprehensive brand name safety testing conducted by Brandsymbol’s Regulatory Risk Assessment division (https://brandsymbol.com/name-safety-testing-tools-brand-development/), supporting its path to regulatory success.

The FDA’s approval of ARYNTA™ reflects Brandsymbol’s continued commitment to enabling brand readiness through strategic, evidence-based risk assessment—ensuring that brand names meet both regulatory and market demands with confidence.

Keep up with recent news: https://azurity.com/news/

Note: The ARYNTA™ label may appear alongside CSL Behring’s new approval for ANDEMBRY™ (garadacimab-gxii) within a shared file on Drugs@FDA.